Oakes Benjamin L.
SEC insider (Form 3/4/5 filer). CIK 0002127814. President, CEO at Scribe Therapeutics, Inc. (SCTX). 3 reported Form 4/5 transactions since Sep 2024; latest on Jul 23, 2026. Located in ALAMEDA, CA.
Companies Oakes Benjamin L. has filed insider reports for
- Scribe Therapeutics, Inc. (SCTX): Director, Officer, President, CEO
Oakes Benjamin L.
CIK: 0002127814
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Scribe Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
264.8K shares- - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
AwardDirectPerformance-based Stock Option (Right to Buy)
429.6K shares- - Mar 13, 2026SCTX
Scribe Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
13K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award Stock Option (Right to Buy) | 264,784 | - | - | Direct |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award Performance-based Stock Option (Right to Buy) | 429,599 | - | - | Direct |
| Mar 13, 2026 | SCTX Scribe Therapeutics, Inc. | Award Stock Option (Right to Buy) | 12,969 | - | - | Direct |
1-3 of 3 transactions